#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6.
1-1	0-2	6.	_	_	_	_

#Text=What do the Clinical Data Teach Us ?
2-1	3-7	What	_	_	_	_
2-2	8-10	do	_	_	_	_
2-3	11-14	the	abstract[1]	new[1]	_	_
2-4	15-23	Clinical	abstract[1]	new[1]	_	_
2-5	24-28	Data	abstract[1]	new[1]	_	_
2-6	29-34	Teach	person[2]	acc[2]	_	_
2-7	35-37	Us	person[2]	acc[2]	_	_
2-8	38-39	?	_	_	_	_

#Text=As discussed above , the great majority of the radiobiological investigations have been done with very radioresistant and hyper-radiosensitive cells .
3-1	40-42	As	_	_	_	_
3-2	43-52	discussed	_	_	_	_
3-3	53-58	above	_	_	_	_
3-4	59-60	,	_	_	_	_
3-5	61-64	the	event[3]	new[3]	_	_
3-6	65-70	great	event[3]	new[3]	_	_
3-7	71-79	majority	event[3]	new[3]	_	_
3-8	80-82	of	event[3]	new[3]	_	_
3-9	83-86	the	event[3]|event[4]	new[3]|new[4]	_	_
3-10	87-102	radiobiological	event[3]|event[4]	new[3]|new[4]	_	_
3-11	103-117	investigations	event[3]|event[4]	new[3]|new[4]	_	_
3-12	118-122	have	_	_	_	_
3-13	123-127	been	_	_	_	_
3-14	128-132	done	_	_	_	_
3-15	133-137	with	_	_	_	_
3-16	138-142	very	object[5]	new[5]	coref	10-3[50_5]
3-17	143-157	radioresistant	object[5]	new[5]	_	_
3-18	158-161	and	object[5]	new[5]	_	_
3-19	162-182	hyper-radiosensitive	object[5]	new[5]	_	_
3-20	183-188	cells	object[5]	new[5]	_	_
3-21	189-190	.	_	_	_	_

#Text=However , the hyper-radiosensitive and hyper-radioresistant cellular models are not representative of the clinical reality .
4-1	191-198	However	_	_	_	_
4-2	199-200	,	_	_	_	_
4-3	201-204	the	abstract[7]	new[7]	coref	17-9[113_7]
4-4	205-225	hyper-radiosensitive	abstract[7]	new[7]	_	_
4-5	226-229	and	abstract[7]	new[7]	_	_
4-6	230-250	hyper-radioresistant	abstract[7]	new[7]	_	_
4-7	251-259	cellular	abstract|abstract[7]	new|new[7]	_	_
4-8	260-266	models	abstract[7]	new[7]	_	_
4-9	267-270	are	_	_	_	_
4-10	271-274	not	_	_	_	_
4-11	275-289	representative	_	_	_	_
4-12	290-292	of	_	_	_	_
4-13	293-296	the	abstract[8]	new[8]	_	_
4-14	297-305	clinical	abstract[8]	new[8]	_	_
4-15	306-313	reality	abstract[8]	new[8]	_	_
4-16	314-315	.	_	_	_	_

#Text=For example , there is no known human genetic syndromes caused by mutations of Ku or DNA-PKcs proteins , the major NHEJ actors .
5-1	316-319	For	_	_	_	_
5-2	320-327	example	_	_	_	_
5-3	328-329	,	_	_	_	_
5-4	330-335	there	_	_	_	_
5-5	336-338	is	_	_	_	_
5-6	339-341	no	abstract[9]	new[9]	coref	11-12[57_9]
5-7	342-347	known	abstract[9]	new[9]	_	_
5-8	348-353	human	abstract[9]	new[9]	_	_
5-9	354-361	genetic	abstract[9]	new[9]	_	_
5-10	362-371	syndromes	abstract[9]	new[9]	_	_
5-11	372-378	caused	_	_	_	_
5-12	379-381	by	_	_	_	_
5-13	382-391	mutations	abstract[10]	new[10]	_	_
5-14	392-394	of	abstract[10]	new[10]	_	_
5-15	395-397	Ku	abstract[10]|abstract	new[10]|new	_	_
5-16	398-400	or	abstract[10]	new[10]	_	_
5-17	401-409	DNA-PKcs	abstract[10]|abstract|substance[13]	new[10]|new|new[13]	coref|coref	11-5[55_13]|17-29[119_0]
5-18	410-418	proteins	abstract[10]|substance[13]	new[10]|new[13]	_	_
5-19	419-420	,	abstract[10]	new[10]	_	_
5-20	421-424	the	abstract[10]|person[15]	new[10]|new[15]	_	_
5-21	425-430	major	abstract[10]|person[15]	new[10]|new[15]	_	_
5-22	431-435	NHEJ	abstract[10]|abstract|person[15]	new[10]|new|new[15]	coref	6-9
5-23	436-442	actors	abstract[10]|person[15]	new[10]|new[15]	_	_
5-24	443-444	.	_	_	_	_

#Text=The only human case of gross defect in NHEJ function to non-viability was caused by mutations of DNA ligase IV ( LIG4 ) .
6-1	445-448	The	abstract[16]	new[16]	_	_
6-2	449-453	only	abstract[16]	new[16]	_	_
6-3	454-459	human	abstract[16]	new[16]	_	_
6-4	460-464	case	abstract[16]	new[16]	_	_
6-5	465-467	of	abstract[16]	new[16]	_	_
6-6	468-473	gross	abstract[16]|abstract[17]	new[16]|new[17]	coref	14-9[83_17]
6-7	474-480	defect	abstract[16]|abstract[17]	new[16]|new[17]	_	_
6-8	481-483	in	abstract[16]|abstract[17]	new[16]|new[17]	_	_
6-9	484-488	NHEJ	abstract[16]|abstract[17]|organization|abstract[19]	new[16]|new[17]|giv|new[19]	coref	17-32
6-10	489-497	function	abstract[16]|abstract[17]|abstract[19]	new[16]|new[17]|new[19]	_	_
6-11	498-500	to	abstract[16]|abstract[17]|abstract[19]	new[16]|new[17]|new[19]	_	_
6-12	501-514	non-viability	abstract[16]|abstract[17]|abstract[19]	new[16]|new[17]|new[19]	_	_
6-13	515-518	was	_	_	_	_
6-14	519-525	caused	_	_	_	_
6-15	526-528	by	_	_	_	_
6-16	529-538	mutations	abstract[20]	new[20]	coref	7-24[32_20]
6-17	539-541	of	abstract[20]	new[20]	_	_
6-18	542-545	DNA	abstract[20]|abstract	new[20]|new	_	_
6-19	546-552	ligase	_	_	_	_
6-20	553-555	IV	abstract[22]	new[22]	_	_
6-21	556-557	(	abstract[22]	new[22]	_	_
6-22	558-562	LIG4	abstract[22]|substance	new[22]|new	coref	15-17
6-23	563-564	)	abstract[22]	new[22]	_	_
6-24	565-566	.	_	_	_	_

#Text=The majority of cases of fatal post-radiotherapy events were encountered after whole-body irradiation of children with ataxia telangiectasia ( AT ) caused by homozygous ATM mutations during their anti-leukemia or lymphoma treatment .
7-1	567-570	The	abstract[24]	new[24]	_	_
7-2	571-579	majority	abstract[24]	new[24]	_	_
7-3	580-582	of	abstract[24]	new[24]	_	_
7-4	583-588	cases	abstract[24]	new[24]	_	_
7-5	589-591	of	abstract[24]	new[24]	_	_
7-6	592-597	fatal	abstract[24]|abstract[26]	new[24]|new[26]	_	_
7-7	598-615	post-radiotherapy	abstract[24]|organization|abstract[26]	new[24]|new|new[26]	_	_
7-8	616-622	events	abstract[24]|abstract[26]	new[24]|new[26]	_	_
7-9	623-627	were	_	_	_	_
7-10	628-639	encountered	_	_	_	_
7-11	640-645	after	_	_	_	_
7-12	646-656	whole-body	abstract[27]	new[27]	coref	21-18[0_27]
7-13	657-668	irradiation	abstract[27]	new[27]	_	_
7-14	669-671	of	abstract[27]	new[27]	_	_
7-15	672-680	children	abstract[27]|person	new[27]|new	ana	7-28
7-16	681-685	with	abstract[27]	new[27]	_	_
7-17	686-692	ataxia	abstract[27]|abstract[29]	new[27]|new[29]	_	_
7-18	693-707	telangiectasia	abstract[27]|abstract[29]	new[27]|new[29]	_	_
7-19	708-709	(	_	_	_	_
7-20	710-712	AT	_	_	_	_
7-21	713-714	)	_	_	_	_
7-22	715-721	caused	_	_	_	_
7-23	722-724	by	_	_	_	_
7-24	725-735	homozygous	person|abstract[32]	new|giv[32]	coref	11-7[56_32]
7-25	736-739	ATM	object|abstract[32]	new|giv[32]	coref	15-20
7-26	740-749	mutations	abstract[32]	giv[32]	_	_
7-27	750-756	during	abstract[32]	giv[32]	_	_
7-28	757-762	their	abstract[32]|person|abstract[34]|event[36]	giv[32]|giv|new[34]|new[36]	_	_
7-29	763-776	anti-leukemia	abstract[32]|abstract[34]|event[36]	giv[32]|new[34]|new[36]	_	_
7-30	777-779	or	abstract[32]|event[36]	giv[32]|new[36]	_	_
7-31	780-788	lymphoma	abstract[32]|abstract|event[36]	giv[32]|new|new[36]	_	_
7-32	789-798	treatment	abstract[32]|event[36]	giv[32]|new[36]	_	_
7-33	799-800	.	_	_	_	_

#Text=It is important to note that AT frequency is of about 1/100,000 .
8-1	801-803	It	abstract	new	cata	8-1[0_38]
8-2	804-806	is	_	_	_	_
8-3	807-816	important	_	_	_	_
8-4	817-819	to	abstract[38]	new[38]	_	_
8-5	820-824	note	abstract[38]	new[38]	_	_
8-6	825-829	that	abstract[38]	new[38]	_	_
8-7	830-832	AT	abstract[38]	new[38]	_	_
8-8	833-842	frequency	abstract[38]|abstract	new[38]|new	_	_
8-9	843-845	is	abstract[38]	new[38]	_	_
8-10	846-848	of	abstract[38]	new[38]	_	_
8-11	849-854	about	abstract[38]|quantity[40]	new[38]|new[40]	_	_
8-12	855-864	1/100,000	abstract[38]|quantity[40]	new[38]|new[40]	_	_
8-13	865-866	.	_	_	_	_

#Text=By contrast , about 5 % – 20 % cancer of patients treated by radiotherapy exhibit post-radiotherapy tissue reactions that can be considered as moderate radiosensitivity .
9-1	867-869	By	_	_	_	_
9-2	870-878	contrast	abstract	new	coref	25-2
9-3	879-880	,	_	_	_	_
9-4	881-886	about	quantity[42]	new[42]	_	_
9-5	887-888	5	quantity[42]	new[42]	_	_
9-6	889-890	%	quantity[42]	new[42]	_	_
9-7	891-892	–	quantity[42]	new[42]	_	_
9-8	893-895	20	quantity[42]|quantity[43]	new[42]|new[43]	_	_
9-9	896-897	%	quantity[42]|quantity[43]	new[42]|new[43]	_	_
9-10	898-904	cancer	abstract[44]	new[44]	coref	12-12[0_44]
9-11	905-907	of	abstract[44]	new[44]	_	_
9-12	908-916	patients	abstract[44]|person	new[44]|new	_	_
9-13	917-924	treated	_	_	_	_
9-14	925-927	by	_	_	_	_
9-15	928-940	radiotherapy	abstract	new	_	_
9-16	941-948	exhibit	_	_	_	_
9-17	949-966	post-radiotherapy	abstract[48]	new[48]	ana	11-3[54_48]
9-18	967-973	tissue	object|abstract[48]	new|new[48]	_	_
9-19	974-983	reactions	abstract[48]	new[48]	_	_
9-20	984-988	that	_	_	_	_
9-21	989-992	can	_	_	_	_
9-22	993-995	be	_	_	_	_
9-23	996-1006	considered	_	_	_	_
9-24	1007-1009	as	_	_	_	_
9-25	1010-1018	moderate	_	_	_	_
9-26	1019-1035	radiosensitivity	_	_	_	_
9-27	1036-1037	.	_	_	_	_

#Text=Surprisingly , no or very few rodent cells with moderate radiosensitivity have been the subject of a published radiobiological characterization .
10-1	1038-1050	Surprisingly	_	_	_	_
10-2	1051-1052	,	_	_	_	_
10-3	1053-1055	no	object[50]	giv[50]	coref	10-14[52_50]
10-4	1056-1058	or	object[50]	giv[50]	_	_
10-5	1059-1063	very	object[50]	giv[50]	_	_
10-6	1064-1067	few	object[50]	giv[50]	_	_
10-7	1068-1074	rodent	animal|object[50]	new|giv[50]	_	_
10-8	1075-1080	cells	object[50]	giv[50]	_	_
10-9	1081-1085	with	object[50]	giv[50]	_	_
10-10	1086-1094	moderate	object[50]|abstract[51]	giv[50]|new[51]	coref	12-23[65_51]
10-11	1095-1111	radiosensitivity	object[50]|abstract[51]	giv[50]|new[51]	_	_
10-12	1112-1116	have	_	_	_	_
10-13	1117-1121	been	_	_	_	_
10-14	1122-1125	the	object[52]	giv[52]	coref	15-21[93_52]
10-15	1126-1133	subject	object[52]	giv[52]	_	_
10-16	1134-1136	of	object[52]	giv[52]	_	_
10-17	1137-1138	a	object[52]|abstract[53]	giv[52]|new[53]	_	_
10-18	1139-1148	published	object[52]|abstract[53]	giv[52]|new[53]	_	_
10-19	1149-1164	radiobiological	object[52]|abstract[53]	giv[52]|new[53]	_	_
10-20	1165-1181	characterization	object[52]|abstract[53]	giv[52]|new[53]	_	_
10-21	1182-1183	.	_	_	_	_

#Text=Interestingly , some of the proteins whose mutations are responsible for these syndromes were cited as components of the different variants of A-NHEJ ( see Section 4 ) .
11-1	1184-1197	Interestingly	_	_	_	_
11-2	1198-1199	,	_	_	_	_
11-3	1200-1204	some	abstract[54]	giv[54]	_	_
11-4	1205-1207	of	abstract[54]	giv[54]	_	_
11-5	1208-1211	the	abstract[54]|substance[55]	giv[54]|giv[55]	coref	13-13[76_55]
11-6	1212-1220	proteins	abstract[54]|substance[55]	giv[54]|giv[55]	_	_
11-7	1221-1226	whose	abstract[56]	giv[56]	_	_
11-8	1227-1236	mutations	abstract[56]	giv[56]	_	_
11-9	1237-1240	are	_	_	_	_
11-10	1241-1252	responsible	_	_	_	_
11-11	1253-1256	for	_	_	_	_
11-12	1257-1262	these	abstract[57]	giv[57]	coref	12-4[61_57]
11-13	1263-1272	syndromes	abstract[57]	giv[57]	_	_
11-14	1273-1277	were	_	_	_	_
11-15	1278-1283	cited	_	_	_	_
11-16	1284-1286	as	_	_	_	_
11-17	1287-1297	components	_	_	_	_
11-18	1298-1300	of	_	_	_	_
11-19	1301-1304	the	abstract[58]	new[58]	_	_
11-20	1305-1314	different	abstract[58]	new[58]	_	_
11-21	1315-1323	variants	abstract[58]	new[58]	_	_
11-22	1324-1326	of	abstract[58]	new[58]	_	_
11-23	1327-1333	A-NHEJ	abstract[58]|abstract	new[58]|new	_	_
11-24	1334-1335	(	_	_	_	_
11-25	1336-1339	see	_	_	_	_
11-26	1340-1347	Section	abstract[60]	new[60]	_	_
11-27	1348-1349	4	abstract[60]	new[60]	_	_
11-28	1350-1351	)	_	_	_	_
11-29	1352-1353	.	_	_	_	_

#Text=In addition , some genetic syndromes , associated or not with cancer proneness , different from the precited ones , also show a moderate radiosensitivity : this is notably the case of neurofibromatosis , Huntington ’s chorea , and tuberous sclerosis syndromes .
12-1	1354-1356	In	_	_	_	_
12-2	1357-1365	addition	_	_	_	_
12-3	1366-1367	,	_	_	_	_
12-4	1368-1372	some	abstract[61]	giv[61]	coref	12-40[72_61]
12-5	1373-1380	genetic	abstract[61]	giv[61]	_	_
12-6	1381-1390	syndromes	abstract[61]	giv[61]	_	_
12-7	1391-1392	,	_	_	_	_
12-8	1393-1403	associated	_	_	_	_
12-9	1404-1406	or	_	_	_	_
12-10	1407-1410	not	_	_	_	_
12-11	1411-1415	with	_	_	_	_
12-12	1416-1422	cancer	abstract|abstract[63]	giv|new[63]	coref|coref	25-20|25-20[171_63]
12-13	1423-1432	proneness	abstract[63]	new[63]	_	_
12-14	1433-1434	,	_	_	_	_
12-15	1435-1444	different	_	_	_	_
12-16	1445-1449	from	_	_	_	_
12-17	1450-1453	the	abstract[64]	new[64]	_	_
12-18	1454-1462	precited	abstract[64]	new[64]	_	_
12-19	1463-1467	ones	abstract[64]	new[64]	_	_
12-20	1468-1469	,	_	_	_	_
12-21	1470-1474	also	_	_	_	_
12-22	1475-1479	show	_	_	_	_
12-23	1480-1481	a	abstract[65]	giv[65]	ana	12-27[0_65]
12-24	1482-1490	moderate	abstract[65]	giv[65]	_	_
12-25	1491-1507	radiosensitivity	abstract[65]	giv[65]	_	_
12-26	1508-1509	:	_	_	_	_
12-27	1510-1514	this	abstract	giv	coref	12-29[67_0]
12-28	1515-1517	is	_	_	_	_
12-29	1518-1525	notably	abstract[67]	giv[67]	ana	13-1[0_67]
12-30	1526-1529	the	abstract[67]	giv[67]	_	_
12-31	1530-1534	case	abstract[67]	giv[67]	_	_
12-32	1535-1537	of	abstract[67]	giv[67]	_	_
12-33	1538-1555	neurofibromatosis	abstract[67]|abstract	giv[67]|new	_	_
12-34	1556-1557	,	abstract[67]	giv[67]	_	_
12-35	1558-1568	Huntington	abstract[67]|place[69]|abstract[70]	giv[67]|new[69]|new[70]	_	_
12-36	1569-1571	’s	abstract[67]|place[69]|abstract[70]	giv[67]|new[69]|new[70]	_	_
12-37	1572-1578	chorea	abstract[67]|abstract[70]	giv[67]|new[70]	_	_
12-38	1579-1580	,	abstract[67]	giv[67]	_	_
12-39	1581-1584	and	abstract[67]	giv[67]	_	_
12-40	1585-1593	tuberous	abstract[67]|abstract[72]	giv[67]|giv[72]	coref	13-6[74_72]
12-41	1594-1603	sclerosis	abstract[67]|abstract|abstract[72]	giv[67]|new|giv[72]	_	_
12-42	1604-1613	syndromes	abstract[67]|abstract[72]	giv[67]|giv[72]	_	_
12-43	1614-1615	.	_	_	_	_

#Text=It must be stressed that these syndromes are caused by mutations of cytoplasmic proteins , which may contradict the historical hypothesis that nucleus is the most radiosensitive part of the cell ( see the Introduction ) .
13-1	1616-1618	It	abstract	giv	coref	14-18[87_0]
13-2	1619-1623	must	_	_	_	_
13-3	1624-1626	be	_	_	_	_
13-4	1627-1635	stressed	_	_	_	_
13-5	1636-1640	that	_	_	_	_
13-6	1641-1646	these	abstract[74]	giv[74]	coref	17-37[121_74]
13-7	1647-1656	syndromes	abstract[74]	giv[74]	_	_
13-8	1657-1660	are	_	_	_	_
13-9	1661-1667	caused	_	_	_	_
13-10	1668-1670	by	_	_	_	_
13-11	1671-1680	mutations	abstract[75]	new[75]	_	_
13-12	1681-1683	of	abstract[75]	new[75]	_	_
13-13	1684-1695	cytoplasmic	abstract[75]|substance[76]	new[75]|giv[76]	_	_
13-14	1696-1704	proteins	abstract[75]|substance[76]	new[75]|giv[76]	_	_
13-15	1705-1706	,	_	_	_	_
13-16	1707-1712	which	_	_	_	_
13-17	1713-1716	may	_	_	_	_
13-18	1717-1727	contradict	_	_	_	_
13-19	1728-1731	the	abstract[77]	new[77]	coref	14-6[82_77]
13-20	1732-1742	historical	abstract[77]	new[77]	_	_
13-21	1743-1753	hypothesis	abstract[77]	new[77]	_	_
13-22	1754-1758	that	abstract[77]	new[77]	_	_
13-23	1759-1766	nucleus	abstract[77]|place	new[77]|new	coref	21-31[144_0]
13-24	1767-1769	is	abstract[77]	new[77]	_	_
13-25	1770-1773	the	abstract[77]	new[77]	_	_
13-26	1774-1778	most	abstract[77]	new[77]	_	_
13-27	1779-1793	radiosensitive	abstract[77]	new[77]	_	_
13-28	1794-1798	part	abstract[77]	new[77]	_	_
13-29	1799-1801	of	abstract[77]	new[77]	_	_
13-30	1802-1805	the	abstract[77]|abstract[79]	new[77]|new[79]	_	_
13-31	1806-1810	cell	abstract[77]|abstract[79]	new[77]|new[79]	_	_
13-32	1811-1812	(	_	_	_	_
13-33	1813-1816	see	_	_	_	_
13-34	1817-1820	the	abstract[80]	new[80]	ana	14-3[0_80]
13-35	1821-1833	Introduction	abstract[80]	new[80]	_	_
13-36	1834-1835	)	_	_	_	_
13-37	1836-1837	.	_	_	_	_

#Text=Furthermore , it also contradicts the hypothesis that defect of DSB repair is the unique cause of cellular radiosensitivity .
14-1	1838-1849	Furthermore	_	_	_	_
14-2	1850-1851	,	_	_	_	_
14-3	1852-1854	it	abstract	giv	_	_
14-4	1855-1859	also	_	_	_	_
14-5	1860-1871	contradicts	_	_	_	_
14-6	1872-1875	the	abstract[82]	giv[82]	coref	21-9[139_82]
14-7	1876-1886	hypothesis	abstract[82]	giv[82]	_	_
14-8	1887-1891	that	_	_	_	_
14-9	1892-1898	defect	abstract[83]	giv[83]	coref	14-14[86_83]
14-10	1899-1901	of	abstract[83]	giv[83]	_	_
14-11	1902-1905	DSB	abstract[83]|abstract|abstract[85]	giv[83]|new|new[85]	coref|coref	15-33|15-34[0_85]
14-12	1906-1912	repair	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
14-13	1913-1915	is	_	_	_	_
14-14	1916-1919	the	abstract[86]	giv[86]	_	_
14-15	1920-1926	unique	abstract[86]	giv[86]	_	_
14-16	1927-1932	cause	abstract[86]	giv[86]	_	_
14-17	1933-1935	of	abstract[86]	giv[86]	_	_
14-18	1936-1944	cellular	abstract[86]|abstract[87]	giv[86]|giv[87]	coref	15-24[94_87]
14-19	1945-1961	radiosensitivity	abstract[86]|abstract[87]	giv[86]|giv[87]	_	_
14-20	1962-1963	.	_	_	_	_

#Text=The question of how to build a unified model that would describe both hyper-radiosensitivity observed in LIG4 - and ATM -mutated cells and moderate radiosensitivity caused by impairment of alternative signaling and DSB repair pathways remains .
15-1	1964-1967	The	abstract[88]	new[88]	_	_
15-2	1968-1976	question	abstract[88]	new[88]	_	_
15-3	1977-1979	of	abstract[88]	new[88]	_	_
15-4	1980-1983	how	abstract[88]	new[88]	_	_
15-5	1984-1986	to	_	_	_	_
15-6	1987-1992	build	_	_	_	_
15-7	1993-1994	a	abstract[89]	new[89]	coref	20-33[132_89]
15-8	1995-2002	unified	abstract[89]	new[89]	_	_
15-9	2003-2008	model	abstract[89]	new[89]	_	_
15-10	2009-2013	that	_	_	_	_
15-11	2014-2019	would	_	_	_	_
15-12	2020-2028	describe	_	_	_	_
15-13	2029-2033	both	abstract[90]	new[90]	coref	34-37[0_90]
15-14	2034-2056	hyper-radiosensitivity	abstract[90]	new[90]	_	_
15-15	2057-2065	observed	_	_	_	_
15-16	2066-2068	in	_	_	_	_
15-17	2069-2073	LIG4	abstract	giv	coref	34-30
15-18	2074-2075	-	_	_	_	_
15-19	2076-2079	and	_	_	_	_
15-20	2080-2083	ATM	object	giv	coref	16-5
15-21	2084-2092	-mutated	object[93]	giv[93]	coref	25-5[165_93]
15-22	2093-2098	cells	object[93]	giv[93]	_	_
15-23	2099-2102	and	object[93]	giv[93]	_	_
15-24	2103-2111	moderate	object[93]|abstract[94]	giv[93]|giv[94]	coref	20-24[0_94]
15-25	2112-2128	radiosensitivity	object[93]|abstract[94]	giv[93]|giv[94]	_	_
15-26	2129-2135	caused	_	_	_	_
15-27	2136-2138	by	_	_	_	_
15-28	2139-2149	impairment	abstract[95]	new[95]	_	_
15-29	2150-2152	of	abstract[95]	new[95]	_	_
15-30	2153-2164	alternative	abstract[95]|abstract[96]	new[95]|new[96]	_	_
15-31	2165-2174	signaling	abstract[95]|abstract[96]	new[95]|new[96]	_	_
15-32	2175-2178	and	abstract[95]	new[95]	_	_
15-33	2179-2182	DSB	abstract[95]|abstract|abstract[99]	new[95]|giv|new[99]	coref	16-16
15-34	2183-2189	repair	abstract[95]|abstract|abstract[99]	new[95]|giv|new[99]	coref	17-12
15-35	2190-2198	pathways	abstract[95]|abstract[99]	new[95]|new[99]	_	_
15-36	2199-2206	remains	_	_	_	_
15-37	2207-2208	.	_	_	_	_

#Text=To date , the ATM protein has been considered as an early actor of the DSB recognition via its phosphorylation of H2AX and the individual radiation response .
16-1	2209-2211	To	_	_	_	_
16-2	2212-2216	date	time	new	_	_
16-3	2217-2218	,	_	_	_	_
16-4	2219-2222	the	substance[102]	new[102]	ana	16-19[0_102]
16-5	2223-2226	ATM	object|substance[102]	giv|new[102]	coref	17-3
16-6	2227-2234	protein	substance[102]	new[102]	_	_
16-7	2235-2238	has	_	_	_	_
16-8	2239-2243	been	_	_	_	_
16-9	2244-2254	considered	_	_	_	_
16-10	2255-2257	as	_	_	_	_
16-11	2258-2260	an	_	_	_	_
16-12	2261-2266	early	_	_	_	_
16-13	2267-2272	actor	_	_	_	_
16-14	2273-2275	of	_	_	_	_
16-15	2276-2279	the	abstract[104]	new[104]	_	_
16-16	2280-2283	DSB	abstract|abstract[104]	giv|new[104]	coref	17-11
16-17	2284-2295	recognition	abstract[104]	new[104]	_	_
16-18	2296-2299	via	abstract[104]	new[104]	_	_
16-19	2300-2303	its	abstract[104]|substance|abstract[106]	new[104]|giv|new[106]	coref	20-10[127_0]
16-20	2304-2319	phosphorylation	abstract[104]|abstract[106]	new[104]|new[106]	_	_
16-21	2320-2322	of	abstract[104]|abstract[106]	new[104]|new[106]	_	_
16-22	2323-2327	H2AX	abstract[104]|abstract[106]|abstract	new[104]|new[106]|new	coref	22-9
16-23	2328-2331	and	abstract[104]	new[104]	_	_
16-24	2332-2335	the	abstract[104]|abstract[109]	new[104]|new[109]	coref	20-41[135_109]
16-25	2336-2346	individual	abstract[104]|abstract[109]	new[104]|new[109]	_	_
16-26	2347-2356	radiation	abstract[104]|abstract|abstract[109]	new[104]|new|new[109]	coref	20-43
16-27	2357-2365	response	abstract[104]|abstract[109]	new[104]|new[109]	_	_
16-28	2366-2367	.	_	_	_	_

#Text=Surprisingly , ATM has not been integrated in all the DSB repair models discussed above while mutations of RAD51 and RAD52 ( for HR ) and Ku and DNA-PKcs ( for NHEJ ) do not cause any viable syndromes in humans (
17-1	2368-2380	Surprisingly	_	_	_	_
17-2	2381-2382	,	_	_	_	_
17-3	2383-2386	ATM	object	giv	coref	20-10
17-4	2387-2390	has	_	_	_	_
17-5	2391-2394	not	_	_	_	_
17-6	2395-2399	been	_	_	_	_
17-7	2400-2410	integrated	_	_	_	_
17-8	2411-2413	in	_	_	_	_
17-9	2414-2417	all	abstract[113]	giv[113]	coref	35-26[235_113]
17-10	2418-2421	the	abstract[113]	giv[113]	_	_
17-11	2422-2425	DSB	abstract|abstract[113]	giv|giv[113]	coref	22-12
17-12	2426-2432	repair	abstract|abstract[113]	giv|giv[113]	coref	23-9
17-13	2433-2439	models	abstract[113]	giv[113]	_	_
17-14	2440-2449	discussed	_	_	_	_
17-15	2450-2455	above	_	_	_	_
17-16	2456-2461	while	_	_	_	_
17-17	2462-2471	mutations	abstract[114]	new[114]	_	_
17-18	2472-2474	of	abstract[114]	new[114]	_	_
17-19	2475-2480	RAD51	abstract[114]|abstract	new[114]|new	_	_
17-20	2481-2484	and	abstract[114]	new[114]	_	_
17-21	2485-2490	RAD52	abstract[114]|abstract[116]	new[114]|new[116]	_	_
17-22	2491-2492	(	abstract[114]|abstract[116]	new[114]|new[116]	_	_
17-23	2493-2496	for	abstract[114]|abstract[116]	new[114]|new[116]	_	_
17-24	2497-2499	HR	abstract[114]|abstract[116]|abstract	new[114]|new[116]|new	_	_
17-25	2500-2501	)	abstract[114]|abstract[116]	new[114]|new[116]	_	_
17-26	2502-2505	and	_	_	_	_
17-27	2506-2508	Ku	abstract	new	_	_
17-28	2509-2512	and	_	_	_	_
17-29	2513-2521	DNA-PKcs	abstract[119]	giv[119]	_	_
17-30	2522-2523	(	abstract[119]	giv[119]	_	_
17-31	2524-2527	for	abstract[119]	giv[119]	_	_
17-32	2528-2532	NHEJ	abstract[119]|abstract	giv[119]|giv	coref	22-17
17-33	2533-2534	)	abstract[119]	giv[119]	_	_
17-34	2535-2537	do	_	_	_	_
17-35	2538-2541	not	_	_	_	_
17-36	2542-2547	cause	_	_	_	_
17-37	2548-2551	any	abstract[121]	giv[121]	coref	35-10[0_121]
17-38	2552-2558	viable	abstract[121]	giv[121]	_	_
17-39	2559-2568	syndromes	abstract[121]	giv[121]	_	_
17-40	2569-2571	in	abstract[121]	giv[121]	_	_
17-41	2572-2578	humans	abstract[121]|person	giv[121]|new	_	_
17-42	2579-2580	(	_	_	_	_

#Text=Figure 1
18-1	2581-2587	Figure	object[123]	new[123]	_	_
18-2	2588-2589	1	object[123]	new[123]	_	_

#Text=) .
19-1	2590-2591	)	_	_	_	_
19-2	2592-2593	.	_	_	_	_

#Text=Recently , the delay in the radiation-induced nucleo-shuttling of ATM protein ( RIANS ) was shown to be a reliable parameter for predicting radiosensitivity and to provide a biologically relevant interpretation of the linear-quadratic model , the mathematical basis of the cellular radiation response .
20-1	2594-2602	Recently	_	_	_	_
20-2	2603-2604	,	_	_	_	_
20-3	2605-2608	the	abstract[124]	new[124]	coref	32-22[201_124]
20-4	2609-2614	delay	abstract[124]	new[124]	_	_
20-5	2615-2617	in	abstract[124]	new[124]	_	_
20-6	2618-2621	the	abstract[124]|substance[125]	new[124]|new[125]	_	_
20-7	2622-2639	radiation-induced	abstract[124]|substance[125]	new[124]|new[125]	_	_
20-8	2640-2656	nucleo-shuttling	abstract[124]|substance[125]	new[124]|new[125]	_	_
20-9	2657-2659	of	abstract[124]|substance[125]	new[124]|new[125]	_	_
20-10	2660-2663	ATM	abstract[124]|substance[125]|object|substance[127]	new[124]|new[125]|giv|giv[127]	coref	21-25
20-11	2664-2671	protein	abstract[124]|substance[125]|substance[127]	new[124]|new[125]|giv[127]	_	_
20-12	2672-2673	(	_	_	_	_
20-13	2674-2679	RIANS	abstract	new	coref	21-6
20-14	2680-2681	)	_	_	_	_
20-15	2682-2685	was	_	_	_	_
20-16	2686-2691	shown	_	_	_	_
20-17	2692-2694	to	_	_	_	_
20-18	2695-2697	be	_	_	_	_
20-19	2698-2699	a	abstract[129]	new[129]	_	_
20-20	2700-2708	reliable	abstract[129]	new[129]	_	_
20-21	2709-2718	parameter	abstract[129]	new[129]	_	_
20-22	2719-2722	for	_	_	_	_
20-23	2723-2733	predicting	_	_	_	_
20-24	2734-2750	radiosensitivity	abstract	giv	coref	25-7[166_0]
20-25	2751-2754	and	_	_	_	_
20-26	2755-2757	to	_	_	_	_
20-27	2758-2765	provide	_	_	_	_
20-28	2766-2767	a	abstract[131]	new[131]	_	_
20-29	2768-2780	biologically	abstract[131]	new[131]	_	_
20-30	2781-2789	relevant	abstract[131]	new[131]	_	_
20-31	2790-2804	interpretation	abstract[131]	new[131]	_	_
20-32	2805-2807	of	abstract[131]	new[131]	_	_
20-33	2808-2811	the	abstract[131]|abstract[132]	new[131]|giv[132]	appos	20-37[133_132]
20-34	2812-2828	linear-quadratic	abstract[131]|abstract[132]	new[131]|giv[132]	_	_
20-35	2829-2834	model	abstract[131]|abstract[132]	new[131]|giv[132]	_	_
20-36	2835-2836	,	_	_	_	_
20-37	2837-2840	the	abstract[133]	giv[133]	coref	21-5[138_133]
20-38	2841-2853	mathematical	abstract[133]	giv[133]	_	_
20-39	2854-2859	basis	abstract[133]	giv[133]	_	_
20-40	2860-2862	of	abstract[133]	giv[133]	_	_
20-41	2863-2866	the	abstract[133]|abstract[135]	giv[133]|giv[135]	coref	35-44[240_135]
20-42	2867-2875	cellular	abstract[133]|abstract[135]	giv[133]|giv[135]	_	_
20-43	2876-2885	radiation	abstract[133]|abstract|abstract[135]	giv[133]|giv|giv[135]	_	_
20-44	2886-2894	response	abstract[133]|abstract[135]	giv[133]|giv[135]	_	_
20-45	2895-2896	.	_	_	_	_

#Text=In the context of the RIANS model , the following mechanistic hypothesis has been proposed : after irradiation , cytoplasmic trans-auto-phosphorylated dimeric forms of ATM become monomeric and diffuse to the nucleus .
21-1	2897-2899	In	_	_	_	_
21-2	2900-2903	the	abstract[136]	new[136]	_	_
21-3	2904-2911	context	abstract[136]	new[136]	_	_
21-4	2912-2914	of	abstract[136]	new[136]	_	_
21-5	2915-2918	the	abstract[136]|abstract[138]	new[136]|giv[138]	coref	35-18[234_138]
21-6	2919-2924	RIANS	abstract[136]|abstract|abstract[138]	new[136]|giv|giv[138]	coref	25-15[169_0]
21-7	2925-2930	model	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
21-8	2931-2932	,	_	_	_	_
21-9	2933-2936	the	abstract[139]	giv[139]	_	_
21-10	2937-2946	following	abstract[139]	giv[139]	_	_
21-11	2947-2958	mechanistic	abstract[139]	giv[139]	_	_
21-12	2959-2969	hypothesis	abstract[139]	giv[139]	_	_
21-13	2970-2973	has	_	_	_	_
21-14	2974-2978	been	_	_	_	_
21-15	2979-2987	proposed	_	_	_	_
21-16	2988-2989	:	_	_	_	_
21-17	2990-2995	after	_	_	_	_
21-18	2996-3007	irradiation	abstract	giv	_	_
21-19	3008-3009	,	_	_	_	_
21-20	3010-3021	cytoplasmic	abstract[142]	new[142]	coref	36-16[245_142]
21-21	3022-3047	trans-auto-phosphorylated	abstract[142]	new[142]	_	_
21-22	3048-3055	dimeric	person|abstract[142]	new|new[142]	_	_
21-23	3056-3061	forms	abstract[142]	new[142]	_	_
21-24	3062-3064	of	abstract[142]	new[142]	_	_
21-25	3065-3068	ATM	abstract[142]|object	new[142]|giv	coref	22-6
21-26	3069-3075	become	_	_	_	_
21-27	3076-3085	monomeric	_	_	_	_
21-28	3086-3089	and	_	_	_	_
21-29	3090-3097	diffuse	_	_	_	_
21-30	3098-3100	to	_	_	_	_
21-31	3101-3104	the	place[144]	giv[144]	coref	24-1[157_144]
21-32	3105-3112	nucleus	place[144]	giv[144]	_	_
21-33	3113-3114	.	_	_	_	_

#Text=In the nucleus , active ATM monomers phosphorylate H2AX molecules at DSB sites , which activates NHEJ .
22-1	3115-3117	In	_	_	_	_
22-2	3118-3121	the	_	_	_	_
22-3	3122-3129	nucleus	_	_	_	_
22-4	3130-3131	,	_	_	_	_
22-5	3132-3138	active	person[146]	new[146]	coref	23-1[153_146]
22-6	3139-3142	ATM	object|person[146]	giv|new[146]	coref	23-2
22-7	3143-3151	monomers	person[146]	new[146]	_	_
22-8	3152-3165	phosphorylate	_	_	_	_
22-9	3166-3170	H2AX	substance|substance[148]	giv|new[148]	_	_
22-10	3171-3180	molecules	substance[148]	new[148]	_	_
22-11	3181-3183	at	substance[148]	new[148]	_	_
22-12	3184-3187	DSB	substance[148]|abstract|place[150]	new[148]|giv|new[150]	coref	23-8
22-13	3188-3193	sites	substance[148]|place[150]	new[148]|new[150]	_	_
22-14	3194-3195	,	_	_	_	_
22-15	3196-3201	which	_	_	_	_
22-16	3202-3211	activates	_	_	_	_
22-17	3212-3216	NHEJ	abstract	giv	_	_
22-18	3217-3218	.	_	_	_	_

#Text=The ATM monomers will re-dimerize during the DSB repair process .
23-1	3219-3222	The	person[153]	giv[153]	_	_
23-2	3223-3226	ATM	object|person[153]	giv|giv[153]	coref	24-5
23-3	3227-3235	monomers	person[153]	giv[153]	_	_
23-4	3236-3240	will	_	_	_	_
23-5	3241-3252	re-dimerize	_	_	_	_
23-6	3253-3259	during	_	_	_	_
23-7	3260-3263	the	abstract[156]	new[156]	_	_
23-8	3264-3267	DSB	abstract|abstract[156]	giv|new[156]	coref	34-24
23-9	3268-3274	repair	abstract|abstract[156]	giv|new[156]	coref	34-25
23-10	3275-3282	process	abstract[156]	new[156]	_	_
23-11	3283-3284	.	_	_	_	_

#Text=Once in nucleus , ATM may also inhibit MRE11 nuclease activity or any other actor responsible for genomic instability .
24-1	3285-3289	Once	place[157]	giv[157]	_	_
24-2	3290-3292	in	place[157]	giv[157]	_	_
24-3	3293-3300	nucleus	place[157]	giv[157]	_	_
24-4	3301-3302	,	_	_	_	_
24-5	3303-3306	ATM	object	giv	coref	25-11
24-6	3307-3310	may	_	_	_	_
24-7	3311-3315	also	_	_	_	_
24-8	3316-3323	inhibit	_	_	_	_
24-9	3324-3329	MRE11	abstract|abstract[161]	new|new[161]	_	_
24-10	3330-3338	nuclease	event|abstract[161]	new|new[161]	_	_
24-11	3339-3347	activity	abstract[161]	new[161]	_	_
24-12	3348-3350	or	_	_	_	_
24-13	3351-3354	any	person[162]	new[162]	_	_
24-14	3355-3360	other	person[162]	new[162]	_	_
24-15	3361-3366	actor	person[162]	new[162]	_	_
24-16	3367-3378	responsible	person[162]	new[162]	_	_
24-17	3379-3382	for	_	_	_	_
24-18	3383-3390	genomic	abstract[163]	new[163]	_	_
24-19	3391-3402	instability	abstract[163]	new[163]	_	_
24-20	3403-3404	.	_	_	_	_

#Text=By contrast , in cells with moderate radiosensitivity , over-expressed ATM substrates may delay the RIANS , thereby favoring cancer proneness and aging .
25-1	3405-3407	By	_	_	_	_
25-2	3408-3416	contrast	abstract	giv	_	_
25-3	3417-3418	,	_	_	_	_
25-4	3419-3421	in	_	_	_	_
25-5	3422-3427	cells	object[165]	giv[165]	_	_
25-6	3428-3432	with	object[165]	giv[165]	_	_
25-7	3433-3441	moderate	object[165]|abstract[166]	giv[165]|giv[166]	coref	30-4[0_166]
25-8	3442-3458	radiosensitivity	object[165]|abstract[166]	giv[165]|giv[166]	_	_
25-9	3459-3460	,	_	_	_	_
25-10	3461-3475	over-expressed	substance[168]	new[168]	coref	32-34[205_168]
25-11	3476-3479	ATM	object|substance[168]	giv|new[168]	coref	32-32[204_0]
25-12	3480-3490	substrates	substance[168]	new[168]	_	_
25-13	3491-3494	may	_	_	_	_
25-14	3495-3500	delay	_	_	_	_
25-15	3501-3504	the	abstract[169]	giv[169]	coref	31-21[189_169]
25-16	3505-3510	RIANS	abstract[169]	giv[169]	_	_
25-17	3511-3512	,	_	_	_	_
25-18	3513-3520	thereby	_	_	_	_
25-19	3521-3529	favoring	_	_	_	_
25-20	3530-3536	cancer	abstract|abstract[171]|abstract[172]	giv|giv[171]|new[172]	coref|coref|coref	31-37|34-40[224_171]|34-40[225_172]
25-21	3537-3546	proneness	abstract[171]|abstract[172]	giv[171]|new[172]	_	_
25-22	3547-3550	and	abstract[172]	new[172]	_	_
25-23	3551-3556	aging	abstract[172]|abstract	new[172]|new	ana	26-1
25-24	3557-3558	.	_	_	_	_

#Text=This is notably the case for huntingtin , neurofibromin , and tuberin .
26-1	3559-3563	This	abstract	giv	coref	26-3[175_0]
26-2	3564-3566	is	_	_	_	_
26-3	3567-3574	notably	abstract[175]	giv[175]	coref	34-45[226_175]
26-4	3575-3578	the	abstract[175]	giv[175]	_	_
26-5	3579-3583	case	abstract[175]	giv[175]	_	_
26-6	3584-3587	for	abstract[175]	giv[175]	_	_
26-7	3588-3598	huntingtin	abstract[175]|substance	giv[175]|new	_	_
26-8	3599-3600	,	abstract[175]	giv[175]	_	_
26-9	3601-3614	neurofibromin	abstract[175]|substance	giv[175]|new	_	_
26-10	3615-3616	,	abstract[175]	giv[175]	_	_
26-11	3617-3620	and	abstract[175]	giv[175]	_	_
26-12	3621-3628	tuberin	abstract[175]|object	giv[175]|new	_	_
26-13	3629-3630	.	_	_	_	_

#Text=(
27-1	3631-3632	(	_	_	_	_

#Text=Figure 6
28-1	3633-3639	Figure	object[179]	new[179]	_	_
28-2	3640-3641	6	object[179]	new[179]	_	_

#Text=) .
29-1	3642-3643	)	_	_	_	_
29-2	3644-3645	.	_	_	_	_

#Text=Three groups of radiosensitivity have been defined :
30-1	3646-3651	Three	abstract[180]	new[180]	_	_
30-2	3652-3658	groups	abstract[180]	new[180]	_	_
30-3	3659-3661	of	abstract[180]	new[180]	_	_
30-4	3662-3678	radiosensitivity	abstract[180]|abstract	new[180]|giv	coref	32-18[200_0]
30-5	3679-3683	have	_	_	_	_
30-6	3684-3688	been	_	_	_	_
30-7	3689-3696	defined	_	_	_	_
30-8	3697-3698	:	_	_	_	_

#Text=Group I ( about 75 % to 85 % whole population ) represents the normosensitive ( radioresistant ) patients with a rapid RIANS after 2 Gy , a low risk of post-radiotherapy tissue reaction and of cancer
31-1	3699-3704	Group	organization	new	coref	32-1[195_0]
31-2	3705-3706	I	person	acc	_	_
31-3	3707-3708	(	_	_	_	_
31-4	3709-3714	about	quantity[184]	new[184]	_	_
31-5	3715-3717	75	quantity[184]	new[184]	_	_
31-6	3718-3719	%	quantity[184]	new[184]	_	_
31-7	3720-3722	to	quantity[184]	new[184]	_	_
31-8	3723-3725	85	quantity[184]|quantity[185]	new[184]|new[185]	coref	32-8[197_185]
31-9	3726-3727	%	quantity[184]|quantity[185]	new[184]|new[185]	_	_
31-10	3728-3733	whole	person[186]	new[186]	coref	32-10[198_186]
31-11	3734-3744	population	person[186]	new[186]	_	_
31-12	3745-3746	)	_	_	_	_
31-13	3747-3757	represents	_	_	_	_
31-14	3758-3761	the	abstract[187]	new[187]	_	_
31-15	3762-3776	normosensitive	abstract[187]	new[187]	_	_
31-16	3777-3778	(	person[188]	new[188]	coref	32-14[199_188]
31-17	3779-3793	radioresistant	person[188]	new[188]	_	_
31-18	3794-3795	)	person[188]	new[188]	_	_
31-19	3796-3804	patients	person[188]	new[188]	_	_
31-20	3805-3809	with	person[188]	new[188]	_	_
31-21	3810-3811	a	person[188]|abstract[189]	new[188]|giv[189]	coref	35-19[0_189]
31-22	3812-3817	rapid	person[188]|abstract[189]	new[188]|giv[189]	_	_
31-23	3818-3823	RIANS	person[188]|abstract[189]	new[188]|giv[189]	_	_
31-24	3824-3829	after	person[188]|abstract[189]	new[188]|giv[189]	_	_
31-25	3830-3831	2	person[188]|abstract[189]|time[190]	new[188]|giv[189]|new[190]	_	_
31-26	3832-3834	Gy	person[188]|abstract[189]|time[190]	new[188]|giv[189]|new[190]	_	_
31-27	3835-3836	,	_	_	_	_
31-28	3837-3838	a	abstract[191]	new[191]	_	_
31-29	3839-3842	low	abstract[191]	new[191]	_	_
31-30	3843-3847	risk	abstract[191]	new[191]	_	_
31-31	3848-3850	of	abstract[191]	new[191]	_	_
31-32	3851-3868	post-radiotherapy	abstract[191]|event[193]	new[191]|new[193]	_	_
31-33	3869-3875	tissue	abstract[191]|object|event[193]	new[191]|new|new[193]	_	_
31-34	3876-3884	reaction	abstract[191]|event[193]	new[191]|new[193]	_	_
31-35	3885-3888	and	_	_	_	_
31-36	3889-3891	of	_	_	_	_
31-37	3892-3898	cancer	event	giv	coref	33-13

#Text=Group II ( about 5 – 20 % of whole population ) represents the patients who elicit a moderate radiosensitivity with a delay in the RIANS due to the sequestration of ATM by mutated and over-expressed substrates .
32-1	3899-3904	Group	organization[195]	giv[195]	coref	34-1[210_195]
32-2	3905-3907	II	organization[195]	giv[195]	_	_
32-3	3908-3909	(	organization[195]	giv[195]	_	_
32-4	3910-3915	about	organization[195]	giv[195]	_	_
32-5	3916-3917	5	organization[195]	giv[195]	_	_
32-6	3918-3919	–	organization[195]	giv[195]	_	_
32-7	3920-3922	20	organization[195]|quantity	giv[195]|new	_	_
32-8	3923-3924	%	organization[195]|quantity[197]	giv[195]|giv[197]	coref	34-4[211_197]
32-9	3925-3927	of	organization[195]|quantity[197]	giv[195]|giv[197]	_	_
32-10	3928-3933	whole	organization[195]|quantity[197]|person[198]	giv[195]|giv[197]|giv[198]	coref	34-4[212_198]
32-11	3934-3944	population	organization[195]|quantity[197]|person[198]	giv[195]|giv[197]|giv[198]	_	_
32-12	3945-3946	)	organization[195]	giv[195]	_	_
32-13	3947-3957	represents	_	_	_	_
32-14	3958-3961	the	person[199]	giv[199]	coref	33-1[206_199]
32-15	3962-3970	patients	person[199]	giv[199]	_	_
32-16	3971-3974	who	_	_	_	_
32-17	3975-3981	elicit	_	_	_	_
32-18	3982-3983	a	abstract[200]	giv[200]	coref	35-7[229_200]
32-19	3984-3992	moderate	abstract[200]	giv[200]	_	_
32-20	3993-4009	radiosensitivity	abstract[200]	giv[200]	_	_
32-21	4010-4014	with	abstract[200]	giv[200]	_	_
32-22	4015-4016	a	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
32-23	4017-4022	delay	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
32-24	4023-4025	in	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
32-25	4026-4029	the	abstract[200]|abstract[201]|abstract[202]	giv[200]|giv[201]|new[202]	_	_
32-26	4030-4035	RIANS	abstract[200]|abstract[201]|abstract[202]	giv[200]|giv[201]|new[202]	_	_
32-27	4036-4039	due	abstract[200]|abstract[201]|abstract[202]	giv[200]|giv[201]|new[202]	_	_
32-28	4040-4042	to	_	_	_	_
32-29	4043-4046	the	abstract[203]	new[203]	_	_
32-30	4047-4060	sequestration	abstract[203]	new[203]	_	_
32-31	4061-4063	of	abstract[203]	new[203]	_	_
32-32	4064-4067	ATM	abstract[203]|object[204]	new[203]|giv[204]	coref	34-11[0_204]
32-33	4068-4070	by	abstract[203]|object[204]	new[203]|giv[204]	_	_
32-34	4071-4078	mutated	abstract[203]|object[204]|substance[205]	new[203]|giv[204]|giv[205]	_	_
32-35	4079-4082	and	abstract[203]|object[204]|substance[205]	new[203]|giv[204]|giv[205]	_	_
32-36	4083-4097	over-expressed	abstract[203]|object[204]|substance[205]	new[203]|giv[204]|giv[205]	_	_
32-37	4098-4108	substrates	abstract[203]|object[204]|substance[205]	new[203]|giv[204]|giv[205]	_	_
32-38	4109-4110	.	_	_	_	_

#Text=These patients are moderately radiosensitive and may have a high risk of cancer or neurodegeneration .
33-1	4111-4116	These	person[206]	giv[206]	coref	34-10[214_206]
33-2	4117-4125	patients	person[206]	giv[206]	_	_
33-3	4126-4129	are	_	_	_	_
33-4	4130-4140	moderately	_	_	_	_
33-5	4141-4155	radiosensitive	_	_	_	_
33-6	4156-4159	and	_	_	_	_
33-7	4160-4163	may	_	_	_	_
33-8	4164-4168	have	_	_	_	_
33-9	4169-4170	a	abstract[207]	new[207]	_	_
33-10	4171-4175	high	abstract[207]	new[207]	_	_
33-11	4176-4180	risk	abstract[207]	new[207]	_	_
33-12	4181-4183	of	abstract[207]	new[207]	_	_
33-13	4184-4190	cancer	abstract[207]|abstract	new[207]|giv	coref	34-42
33-14	4191-4193	or	abstract[207]	new[207]	_	_
33-15	4194-4211	neurodegeneration	abstract[207]|abstract	new[207]|new	_	_
33-16	4212-4213	.	_	_	_	_

#Text=Group III ( <1 % whole population ) represents the ATM -mutated patients with no functional ATM kinase or those who show strong DSB repair defects ( like the LIG4 -mutated patient described above ) , hyper-radiosensitivity , and either high cancer proneness or severe accelerated aging .
34-1	4214-4219	Group	organization[210]	giv[210]	_	_
34-2	4220-4223	III	organization[210]	giv[210]	_	_
34-3	4224-4225	(	_	_	_	_
34-4	4226-4228	<1	quantity[211]|person[212]	giv[211]|giv[212]	_	_
34-5	4229-4230	%	quantity[211]|person[212]	giv[211]|giv[212]	_	_
34-6	4231-4236	whole	person[212]	giv[212]	_	_
34-7	4237-4247	population	person[212]	giv[212]	_	_
34-8	4248-4249	)	_	_	_	_
34-9	4250-4260	represents	_	_	_	_
34-10	4261-4264	the	person[214]	giv[214]	_	_
34-11	4265-4268	ATM	object|person[214]	giv|giv[214]	coref	34-17
34-12	4269-4277	-mutated	person[214]	giv[214]	_	_
34-13	4278-4286	patients	person[214]	giv[214]	_	_
34-14	4287-4291	with	person[214]	giv[214]	_	_
34-15	4292-4294	no	person[214]|abstract[216]	giv[214]|new[216]	_	_
34-16	4295-4305	functional	person[214]|abstract[216]	giv[214]|new[216]	_	_
34-17	4306-4309	ATM	person[214]|object|abstract[216]	giv[214]|giv|new[216]	coref	35-32
34-18	4310-4316	kinase	person[214]|abstract[216]	giv[214]|new[216]	_	_
34-19	4317-4319	or	person[214]	giv[214]	_	_
34-20	4320-4325	those	person[214]	giv[214]	_	_
34-21	4326-4329	who	_	_	_	_
34-22	4330-4334	show	_	_	_	_
34-23	4335-4341	strong	abstract[219]	new[219]	_	_
34-24	4342-4345	DSB	abstract|abstract[219]	giv|new[219]	coref	36-26
34-25	4346-4352	repair	abstract|abstract[219]	giv|new[219]	coref	36-27
34-26	4353-4360	defects	abstract[219]	new[219]	_	_
34-27	4361-4362	(	abstract[219]	new[219]	_	_
34-28	4363-4367	like	abstract[219]	new[219]	_	_
34-29	4368-4371	the	abstract[219]|person[221]	new[219]|new[221]	_	_
34-30	4372-4376	LIG4	abstract[219]|abstract|person[221]	new[219]|giv|new[221]	_	_
34-31	4377-4385	-mutated	abstract[219]|person[221]	new[219]|new[221]	_	_
34-32	4386-4393	patient	abstract[219]|person[221]	new[219]|new[221]	_	_
34-33	4394-4403	described	abstract[219]	new[219]	_	_
34-34	4404-4409	above	abstract[219]	new[219]	_	_
34-35	4410-4411	)	abstract[219]	new[219]	_	_
34-36	4412-4413	,	abstract[219]	new[219]	_	_
34-37	4414-4436	hyper-radiosensitivity	abstract[219]|abstract	new[219]|giv	_	_
34-38	4437-4438	,	abstract[219]	new[219]	_	_
34-39	4439-4442	and	abstract[219]	new[219]	_	_
34-40	4443-4449	either	abstract[219]|abstract[224]|abstract[225]	new[219]|giv[224]|giv[225]	_	_
34-41	4450-4454	high	abstract[219]|abstract[224]|abstract[225]	new[219]|giv[224]|giv[225]	_	_
34-42	4455-4461	cancer	abstract[219]|abstract|abstract[224]|abstract[225]	new[219]|giv|giv[224]|giv[225]	_	_
34-43	4462-4471	proneness	abstract[219]|abstract[224]|abstract[225]	new[219]|giv[224]|giv[225]	_	_
34-44	4472-4474	or	abstract[219]|abstract[225]	new[219]|giv[225]	_	_
34-45	4475-4481	severe	abstract[219]|abstract[225]|abstract[226]	new[219]|giv[225]|giv[226]	ana	35-2[0_226]
34-46	4482-4493	accelerated	abstract[219]|abstract[225]|abstract[226]	new[219]|giv[225]|giv[226]	_	_
34-47	4494-4499	aging	abstract[219]|abstract[225]|abstract[226]	new[219]|giv[225]|giv[226]	_	_
34-48	4500-4501	.	_	_	_	_

#Text=While it provides relevant explanation of the radiosensitivity of syndromes caused by mutations of cytoplasmic proteins , the RIANS model appears to be compatible with all the alternative models , as ATM is upstream of all the cascades of radiation-induced phosphorylations involved in the individual response to IR .
35-1	4502-4507	While	_	_	_	_
35-2	4508-4510	it	abstract	giv	_	_
35-3	4511-4519	provides	_	_	_	_
35-4	4520-4528	relevant	abstract[228]	new[228]	_	_
35-5	4529-4540	explanation	abstract[228]	new[228]	_	_
35-6	4541-4543	of	abstract[228]	new[228]	_	_
35-7	4544-4547	the	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
35-8	4548-4564	radiosensitivity	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
35-9	4565-4567	of	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
35-10	4568-4577	syndromes	abstract[228]|abstract[229]|abstract	new[228]|giv[229]|giv	_	_
35-11	4578-4584	caused	_	_	_	_
35-12	4585-4587	by	_	_	_	_
35-13	4588-4597	mutations	abstract[231]	new[231]	_	_
35-14	4598-4600	of	abstract[231]	new[231]	_	_
35-15	4601-4612	cytoplasmic	abstract[231]|object[232]	new[231]|new[232]	_	_
35-16	4613-4621	proteins	abstract[231]|object[232]	new[231]|new[232]	_	_
35-17	4622-4623	,	_	_	_	_
35-18	4624-4627	the	abstract[234]	giv[234]	_	_
35-19	4628-4633	RIANS	object|abstract[234]	giv|giv[234]	_	_
35-20	4634-4639	model	abstract[234]	giv[234]	_	_
35-21	4640-4647	appears	_	_	_	_
35-22	4648-4650	to	_	_	_	_
35-23	4651-4653	be	_	_	_	_
35-24	4654-4664	compatible	_	_	_	_
35-25	4665-4669	with	_	_	_	_
35-26	4670-4673	all	abstract[235]	giv[235]	_	_
35-27	4674-4677	the	abstract[235]	giv[235]	_	_
35-28	4678-4689	alternative	abstract[235]	giv[235]	_	_
35-29	4690-4696	models	abstract[235]	giv[235]	_	_
35-30	4697-4698	,	_	_	_	_
35-31	4699-4701	as	_	_	_	_
35-32	4702-4705	ATM	place	giv	coref	35-34[237_0]
35-33	4706-4708	is	_	_	_	_
35-34	4709-4717	upstream	place[237]	giv[237]	coref	36-17[0_237]
35-35	4718-4720	of	place[237]	giv[237]	_	_
35-36	4721-4724	all	place[237]|abstract[238]	giv[237]|new[238]	_	_
35-37	4725-4728	the	place[237]|abstract[238]	giv[237]|new[238]	_	_
35-38	4729-4737	cascades	place[237]|abstract[238]	giv[237]|new[238]	_	_
35-39	4738-4740	of	place[237]|abstract[238]	giv[237]|new[238]	_	_
35-40	4741-4758	radiation-induced	place[237]|abstract[238]|abstract[239]	giv[237]|new[238]|new[239]	_	_
35-41	4759-4775	phosphorylations	place[237]|abstract[238]|abstract[239]	giv[237]|new[238]|new[239]	_	_
35-42	4776-4784	involved	_	_	_	_
35-43	4785-4787	in	_	_	_	_
35-44	4788-4791	the	abstract[240]	giv[240]	_	_
35-45	4792-4802	individual	abstract[240]	giv[240]	_	_
35-46	4803-4811	response	abstract[240]	giv[240]	_	_
35-47	4812-4814	to	abstract[240]	giv[240]	_	_
35-48	4815-4817	IR	abstract[240]|abstract	giv[240]|new	_	_
35-49	4818-4819	.	_	_	_	_

#Text=Obviously , further investigations are needed to better understand the direct or indirect role of cytoplasmic ATM forms in the activation or the inhibition of DSB repair pathways .
36-1	4820-4829	Obviously	_	_	_	_
36-2	4830-4831	,	_	_	_	_
36-3	4832-4839	further	abstract[242]	new[242]	_	_
36-4	4840-4854	investigations	abstract[242]	new[242]	_	_
36-5	4855-4858	are	_	_	_	_
36-6	4859-4865	needed	_	_	_	_
36-7	4866-4868	to	_	_	_	_
36-8	4869-4875	better	_	_	_	_
36-9	4876-4886	understand	_	_	_	_
36-10	4887-4890	the	abstract[243]	new[243]	_	_
36-11	4891-4897	direct	abstract[243]	new[243]	_	_
36-12	4898-4900	or	abstract[243]	new[243]	_	_
36-13	4901-4909	indirect	abstract[243]	new[243]	_	_
36-14	4910-4914	role	abstract[243]	new[243]	_	_
36-15	4915-4917	of	abstract[243]	new[243]	_	_
36-16	4918-4929	cytoplasmic	abstract[243]|abstract[245]	new[243]|giv[245]	_	_
36-17	4930-4933	ATM	abstract[243]|object|abstract[245]	new[243]|giv|giv[245]	_	_
36-18	4934-4939	forms	abstract[243]|abstract[245]	new[243]|giv[245]	_	_
36-19	4940-4942	in	abstract[243]|abstract[245]	new[243]|giv[245]	_	_
36-20	4943-4946	the	abstract[243]|abstract[245]|event[246]	new[243]|giv[245]|new[246]	_	_
36-21	4947-4957	activation	abstract[243]|abstract[245]|event[246]	new[243]|giv[245]|new[246]	_	_
36-22	4958-4960	or	abstract[243]|abstract[245]	new[243]|giv[245]	_	_
36-23	4961-4964	the	abstract[243]|abstract[245]|event[247]	new[243]|giv[245]|new[247]	_	_
36-24	4965-4975	inhibition	abstract[243]|abstract[245]|event[247]	new[243]|giv[245]|new[247]	_	_
36-25	4976-4978	of	abstract[243]|abstract[245]|event[247]	new[243]|giv[245]|new[247]	_	_
36-26	4979-4982	DSB	abstract[243]|abstract[245]|event[247]|abstract|abstract[250]	new[243]|giv[245]|new[247]|giv|new[250]	_	_
36-27	4983-4989	repair	abstract[243]|abstract[245]|event[247]|abstract|abstract[250]	new[243]|giv[245]|new[247]|giv|new[250]	_	_
36-28	4990-4998	pathways	abstract[243]|abstract[245]|event[247]|abstract[250]	new[243]|giv[245]|new[247]|new[250]	_	_
36-29	4999-5000	.	_	_	_	_
